Disc Medicine
在场
是其中之一......
Disc Medicine 是一家在股票代码 IRON (US) 下上市的公司。
涉及Disc Medicine的并购和融资。
- Disc Medicine 刚刚宣布为 60 筹款数百万美元。 (公布2023二月17号).
高管
查看带有其 20 名主要高管的组织结构图
Disc Medicine 搜索最多的简介
- John Quisel, Chief Executive Officer and Director
- Donald Nicholson, Executive Chairman of the Board
- Kevin Bitterman, Director
高管在Disc Medicine变化
- Pamela Stephenson已作为Chief Commercial Officer加入公司 (新闻发布的2024二月27号).
- Joanne Bryce, Chief Financial Officer 请很快离开公司 (新闻发布的2023十月24号).
创建提醒
跟踪 Disc Medicine 的高管变动
生物技术
Disc Medicine 拥有 2,284 家竞争者，其中包括 Lonza (瑞士)、Eurofins (卢森堡) 和 Adaptive Phage Therapeutics (美国(美洲))。
Popular M&A news in 生物技术
- Karius 刚刚宣布为 100 筹款数百万美元。 (公布2024五月3号).
- Transcarent 刚刚宣布为 126 筹款数百万美元。 (公布2024五月2号).
- WindRose Health Investors has announced the acquisition of SubjectWell (公布2024五月2号).
生物技术 行业的其他推荐联系人
消息
Disc Medicine 的最新新闻稿
- Disc Reports Topline Results from Phase 2 AURORA Study of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP) | Disc Medicine Inc.
- Disc Medicine Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update | Disc Medicine Inc.
- Disc Medicine to Participate in the Leerink Partners Global Biopharma Conference 2024 | Disc Medicine Inc.
- Disc Medicine Initiates AURORA, a Phase 2 Clinical Study of Bitopertin in Adults with Erythropoietic Protoporphyria (EPP) - Disc Medicine
- Disc Medicine Announces Several Presentations Across Hematology Portfolio at the 64th American Society of Hematology Annual Meeting - Disc Medicine
- Disc Medicine Announces Multiple Presentations Across Hematology Portfolio at the 64th American Society of Hematology Annual Meeting - Disc Medicine
- Disc Medicine Initiates AURORA, a Phase 2 Clinical Study of Bitopertin in Adults with Erythropoietic Protoporphyria (EPP) - Disc Medicine
- Disc Medicine Initiates BEACON, a Phase 2 Clinical Study of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP) and X-linked Protoporphyria (XLP) - Disc Medicine
- Gemini Therapeutics and Disc Medicine Announce Merger Agreement - Disc Medicine
- Disc Medicine Initiates Phase 1b/2 Clinical Study of DISC-0974 in Myelofibrosis Patients with Severe Anemia - Disc Medicine
- View more press releases Close
关于 Disc Medicine 的社交媒体
保持联系
通过电子邮件联系联系该企业高管，包括 John Quisel 
